---
title: "Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282183755.md"
description: "Recent preclinical findings regarding FHD-909 (also known as LY4050784) have shown promising results, indicating the possibility of further development opportunities when used in conjunction with an anti-PD-1 antibody for SMARCA4 (BRG1)-mutant lung cancer. The data suggests that this combination therapy could be effective in targeting this specific type of lung cancer, potentially leading to improved treatment outcomes. This discovery opens up new avenues for research and development in the field of oncology."
datetime: "2026-04-09T11:01:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282183755.md)
  - [en](https://longbridge.com/en/news/282183755.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282183755.md)
---

# Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Recent preclinical findings regarding FHD-909 (also known as LY4050784) have shown promising results, indicating the possibility of further development opportunities when used in conjunction with an anti-PD-1 antibody for SMARCA4 (BRG1)-mutant lung cancer. The data suggests that this combination therapy could be effective in targeting this specific type of lung cancer, potentially leading to improved treatment outcomes. This discovery opens up new avenues for research and development in the field of oncology.

### Related Stocks

- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FHTX.US](https://longbridge.com/en/quote/FHTX.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [Medicare is about to change a drug program that held down the cost of premiums. Here's what to know.](https://longbridge.com/en/news/294391519.md)
- [HEDGE FLOW-Hedge fund bets on rising US healthcare stocks near 5-year high, Goldman says](https://longbridge.com/en/news/293938581.md)
- [Generic drug sector seeks policy fixes after Trump tariff threat](https://longbridge.com/en/news/293501714.md)
- [Trump Says US To Exempt Import Tariff On Generic Drugs For Two Years](https://longbridge.com/en/news/293481843.md)
- [Biotech experts want FDA drug reviews based on science, not politics](https://longbridge.com/en/news/293453841.md)